Nicholas Saraceno is Editor of Pharmaceutical Commerce. He can be reached at nsaraceno@mjhlifesciences.com.
Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.
In this exclusive PC Podcast interview, Alice Valder Curran, partner at Hogan Lovells, explores:
How recent executive orders—both under the Biden and Trump administrations—have reshaped the drug pricing landscape, and the legal challenges or uncertainties they present for pharmaceutical companies
What life sciences companies should be doing now to proactively prepare for further executive action on drug pricing and market access
The key differences in how executive policies versus legislative actions affect the pharma industry’s pricing and commercialization strategies
The legal and strategic risks executive policy shifts pose to investors and biopharma leaders who may be planning product launches or portfolio expansion over the next few years
The latest episode of The Pharmaceutical Commerce Podcast is available directly on Audioboom, Spotify, or iHeart.
